137 related articles for article (PubMed ID: 7290261)
1. Alterations of plasma levels in malignant lymphoma.
Opat P; Rejthar A; Tomanová J; Trnka A; Wotke R
Neoplasma; 1981; 28(3):339-43. PubMed ID: 7290261
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
3. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment determination of isohaemagglutinin titter values in patients with malignant lymphomas and metastatic solid tumors.
Nikolić L; Budisin Z; Jelić S
Med Sci Monit; 2000; 6(1):63-7. PubMed ID: 11208285
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
8. Lymphocytic characterization in Hodgkin's and non-Hodgkin's lymphoma.
Kamthan M; Joshi N; Sharma ML
Indian J Pathol Microbiol; 1982 Apr; 25(2):139-43. PubMed ID: 6982850
[No Abstract] [Full Text] [Related]
9. [Blood iron and ferritin in the monitoring of Hodgkin's disease].
Garavelli PL
Minerva Med; 1988 Apr; 79(4):263-4. PubMed ID: 3368104
[TBL] [Abstract][Full Text] [Related]
10. [Changes in the factor VIII molecular complex in Hodgkin's disease and non-Hodgkin's lymphoma].
Lisichkov T; Tsekova R
Vutr Boles; 1987; 26(3):69-71. PubMed ID: 3113078
[TBL] [Abstract][Full Text] [Related]
11. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract][Full Text] [Related]
12. Ceruloplasmin in Hodgkin's disease.
Koprivová H; Dienstbier Z; Sámal M; Foltýnová V
Neoplasma; 1982; 29(3):333-40. PubMed ID: 7133228
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
16. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
17. [Plasma hemostasis disorders in Hodgkin's disease and non-Hodgkin's lymphoma].
Zawilska K; Psuja P; Komarnicki M; Sowier J; Wysocki K
Pol Arch Med Wewn; 1981 Aug; 66(2):123-31. PubMed ID: 7322926
[No Abstract] [Full Text] [Related]
18. Serum ceruloplasmin levels in patients of leukaemias, Hodgkin's and non-Hodgkin's lymphomas.
Aggarwal AK; Sanwalka AB; Vadehra PL; Prabhakar BR
Indian J Pathol Microbiol; 1984 Oct; 27(4):347-52. PubMed ID: 6534868
[No Abstract] [Full Text] [Related]
19. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
20. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
